CYP1B1 and CYP19 gene polymorphisms and breast cancer incidence: No association in the ARIC study

Bharat Thyagarajan; Marcia Brott; Pamela Mink; Aaron R. Folsom; Kristin E. Anderson; William Starr Oetting; Myron Gross

doi:10.1016/j.canlet.2003.12.009

CYP1B1 and CYP19 gene polymorphisms and breast cancer incidence: No association in the ARIC study

Bharat Thyagarajan, Marcia Brott, Pamela Mink, Aaron R. Folsom, Kristin E. Anderson, William Starr Oetting, Myron Gross

Research output: Contribution to journal › Article › peer-review

38 Scopus citations

Abstract

We conducted a nested case control study of 178 incident breast cancer cases and 356 controls in the Atherosclerosis Risk in Communities study. We evaluated the association between breast cancer and Val432Leu polymorphism in the CYP1B1 gene and the tetranucleotide repeats in intron 4 of the CYP19 gene. After adjustment for height, age at menopause, age at menarche, BMI, HRT, and alcohol intake, carriers of the Val/Leu or Val/Val genotype had a 1.45 fold (95% CI 0.85-2.47) greater odds of breast cancer than Leu/Leu carriers. There was no association of the breast cancer with any individual CYP19 allele. Compared to individuals homozygous with the 167 allele, odds ratios were close to 1.0 for the 167 heterozygous genotype and for the remaining tetranucleotide repeats combined. Our data shows no association between breast cancer and the Leu432Val polymorphism of the CYP1B1 gene or the tetranucleotide repeats of the CYP19 gene.

Original language	English (US)
Pages (from-to)	183-189
Number of pages	7
Journal	Cancer Letters
Volume	207
Issue number	2
DOIs	https://doi.org/10.1016/j.canlet.2003.12.009
State	Published - Apr 2004

Bibliographical note

Funding Information:
The ARIC Study was supported by NHLBI contracts: N01-HC-55015, N01-HC-55016,N01-HC-55018, N01-HC-55019, N01-HC-55020, N01-HC-55021, and N01-HC-55022. This study was supported by NCI Grant R03-CA65473. The authors thank the staff and participants in ARIC for their long-standing contributions. The authors also thank Fan Kong for her assistance with the laboratory procedures for this study.

Keywords

Breast cancer
CYP19
CYP1B1
Estrogen metabolism
Prospective study

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1016/j.canlet.2003.12.009

Find It

Find It at U of M Libraries

Cite this

@article{3ba29893d640405c81a3e9fe31134416,

title = "CYP1B1 and CYP19 gene polymorphisms and breast cancer incidence: No association in the ARIC study",

abstract = "We conducted a nested case control study of 178 incident breast cancer cases and 356 controls in the Atherosclerosis Risk in Communities study. We evaluated the association between breast cancer and Val432Leu polymorphism in the CYP1B1 gene and the tetranucleotide repeats in intron 4 of the CYP19 gene. After adjustment for height, age at menopause, age at menarche, BMI, HRT, and alcohol intake, carriers of the Val/Leu or Val/Val genotype had a 1.45 fold (95% CI 0.85-2.47) greater odds of breast cancer than Leu/Leu carriers. There was no association of the breast cancer with any individual CYP19 allele. Compared to individuals homozygous with the 167 allele, odds ratios were close to 1.0 for the 167 heterozygous genotype and for the remaining tetranucleotide repeats combined. Our data shows no association between breast cancer and the Leu432Val polymorphism of the CYP1B1 gene or the tetranucleotide repeats of the CYP19 gene.",

keywords = "Breast cancer, CYP19, CYP1B1, Estrogen metabolism, Prospective study",

author = "Bharat Thyagarajan and Marcia Brott and Pamela Mink and Folsom, {Aaron R.} and Anderson, {Kristin E.} and Oetting, {William Starr} and Myron Gross",

note = "Funding Information: The ARIC Study was supported by NHLBI contracts: N01-HC-55015, N01-HC-55016,N01-HC-55018, N01-HC-55019, N01-HC-55020, N01-HC-55021, and N01-HC-55022. This study was supported by NCI Grant R03-CA65473. The authors thank the staff and participants in ARIC for their long-standing contributions. The authors also thank Fan Kong for her assistance with the laboratory procedures for this study.",

year = "2004",

month = apr,

doi = "10.1016/j.canlet.2003.12.009",

language = "English (US)",

volume = "207",

pages = "183--189",

journal = "Cancer Letters",

issn = "0304-3835",

publisher = "Elsevier Ireland Ltd",

number = "2",

}

TY - JOUR

T1 - CYP1B1 and CYP19 gene polymorphisms and breast cancer incidence

T2 - No association in the ARIC study

AU - Thyagarajan, Bharat

AU - Brott, Marcia

AU - Mink, Pamela

AU - Folsom, Aaron R.

AU - Anderson, Kristin E.

AU - Oetting, William Starr

AU - Gross, Myron

N1 - Funding Information: The ARIC Study was supported by NHLBI contracts: N01-HC-55015, N01-HC-55016,N01-HC-55018, N01-HC-55019, N01-HC-55020, N01-HC-55021, and N01-HC-55022. This study was supported by NCI Grant R03-CA65473. The authors thank the staff and participants in ARIC for their long-standing contributions. The authors also thank Fan Kong for her assistance with the laboratory procedures for this study.

PY - 2004/4

Y1 - 2004/4

N2 - We conducted a nested case control study of 178 incident breast cancer cases and 356 controls in the Atherosclerosis Risk in Communities study. We evaluated the association between breast cancer and Val432Leu polymorphism in the CYP1B1 gene and the tetranucleotide repeats in intron 4 of the CYP19 gene. After adjustment for height, age at menopause, age at menarche, BMI, HRT, and alcohol intake, carriers of the Val/Leu or Val/Val genotype had a 1.45 fold (95% CI 0.85-2.47) greater odds of breast cancer than Leu/Leu carriers. There was no association of the breast cancer with any individual CYP19 allele. Compared to individuals homozygous with the 167 allele, odds ratios were close to 1.0 for the 167 heterozygous genotype and for the remaining tetranucleotide repeats combined. Our data shows no association between breast cancer and the Leu432Val polymorphism of the CYP1B1 gene or the tetranucleotide repeats of the CYP19 gene.

AB - We conducted a nested case control study of 178 incident breast cancer cases and 356 controls in the Atherosclerosis Risk in Communities study. We evaluated the association between breast cancer and Val432Leu polymorphism in the CYP1B1 gene and the tetranucleotide repeats in intron 4 of the CYP19 gene. After adjustment for height, age at menopause, age at menarche, BMI, HRT, and alcohol intake, carriers of the Val/Leu or Val/Val genotype had a 1.45 fold (95% CI 0.85-2.47) greater odds of breast cancer than Leu/Leu carriers. There was no association of the breast cancer with any individual CYP19 allele. Compared to individuals homozygous with the 167 allele, odds ratios were close to 1.0 for the 167 heterozygous genotype and for the remaining tetranucleotide repeats combined. Our data shows no association between breast cancer and the Leu432Val polymorphism of the CYP1B1 gene or the tetranucleotide repeats of the CYP19 gene.

KW - Breast cancer

KW - CYP19

KW - CYP1B1

KW - Estrogen metabolism

KW - Prospective study

UR - http://www.scopus.com/inward/record.url?scp=1842452781&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842452781&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2003.12.009

DO - 10.1016/j.canlet.2003.12.009

M3 - Article

C2 - 15072827

AN - SCOPUS:1842452781

SN - 0304-3835

VL - 207

SP - 183

EP - 189

JO - Cancer Letters

JF - Cancer Letters

IS - 2

ER -

CYP1B1 and CYP19 gene polymorphisms and breast cancer incidence: No association in the ARIC study

Abstract

Bibliographical note

Keywords

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this